Enforcement Report - Week of July 5, 2023
Health Canada Issues Recall of Ferring`s Endometrin effervescent vaginal tablets
Enforcement Report - Week of February 1, 2023
The Scottish Medicines Consortium (SMC) has approved Utrogestan, the only adjunctive micronised progesterone available as hormone replacement therapy (HRT) for use alongside any oestrogen-only HRT for women with an intact uterus.
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.
Xiromed's Generic Progesterone Receives Approval in the U.S.
Enforcement Report - Week of November 17, 2021
Pfizer’s contract development and manufacturing organization (CDMO) is now offering services in Nagoya, Japan.
Theramex has recently launched the first and only body-identical hormone therapy treatment (HRT) for post-menopausal women, in the form of Bijuva/Bijuve® (estradiol and progesterone).
LONDON - ( BUSINESS WIRE ) - PRESCRIPTION INFORMATION IS AVAILABLE AT THE END OF THIS PRESS RELEASE - Theramex today launched Bijuva ® / Bijuve ® (1 mg estradiol / 100 mg progesterone) across Europe and the UK. Bijuva ® , (known as Bijuve ® in the UK), is the first and only bioidentical hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus (at less than 12 months since last menstrual period), which combines estradiol and progesterone in a single daily oral capsule. 1,2 Unlike synthetic hormonal products, estradiol and progesterone present in Bijuva ® / Bijuve ®are chemically and biologically identical to hormones that naturally circulate in a woman's body.